J&J's Janssen Pharma Seeks Razadyne Approval In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Janssen Pharmaceutical K.K., a Johnson & Johnson pharmaceutical subsidiary in Japan, applied for distribution and marketing approval for its Alzheimer's disease drug Razadyne (galantamine) with Japan's Ministry of Health, Labor and Welfare, in a market currently monopolized by Eisai's Aricept, a company spokesman said March 2
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)